Cytokinetics Inc Stock Price, News & Analysis

Cytokinetics (NASDAQ:CYTK) presented new data for aficamten at the HFSA Annual Scientific Meeting 2025, showcasing positive results from two studies. The MAPLE-HCM study demonstrated aficamten's superiority over metoprolol in improving exercise capacity, with significant enhancements in both maximal and submaximal exercise performance.

The FOREST-HCM 96-week analysis in non-obstructive HCM patients showed promising long-term efficacy and tolerability. Key findings include 79% of patients improving by at least one NYHA Functional Class, with 74% becoming asymptomatic. The study reported sustained reductions in symptom burden and improvements in cardiac biomarkers, with 82.4% of patients achieving the highest available doses of 15-20 mg.

Cytokinetics (Nasdaq: CYTK) has announced its eighth annual Communications Grant Program, which will award five grants to patient advocacy organizations focused on hypertrophic cardiomyopathy (HCM) and heart failure communities. The program aims to support communications, awareness building, and community engagement initiatives.

Applications for the 2025 grants are open until November 3rd, 2025, with winners to be announced in January 2026. Eligible organizations must be nonprofits or registered charities in the US, Canada, Europe, or UK. Previous recipients include the AICARM APS, HeartBrothers Foundation, HeartCharged Corporation, HCMA, and Stichting Cardiomyopathie Onderzoek Nederland.

Cytokinetics (NASDAQ:CYTK) announced its management team will deliver a corporate update at the upcoming Stifel 2025 Virtual Cardiometabolic Forum. The presentation is scheduled for Tuesday, September 30, 2025 at 10:00 AM Eastern Time.

Investors and interested parties can access the live webcast of the fireside chat through the Investors & Media section of Cytokinetics' website. The webcast recording will remain available on the company's website for 90 days after the event.

Cytokinetics (Nasdaq: CYTK) announced the granting of inducement equity awards to 11 new employees who joined in August and September 2025. The grants include 39,790 stock options at an exercise price of $49.44 per share and 26,822 restricted stock units (RSUs).

The RSUs will vest over 3 years (40% in year 1, 40% in year 2, and 20% in year 3), while the stock options will vest over 4 years (25% after one year, followed by monthly installments). The options have a 10-year term and were granted under the company's Amended and Restated 2004 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Cytokinetics (NASDAQ:CYTK) announced three upcoming presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025 in Minneapolis. Two presentations will be featured in the Late Breaking Clinical Research session on September 28, 2025.

The presentations include long-term 96-week safety and efficacy data from the FOREST-HCM trial studying aficamten in non-obstructive hypertrophic cardiomyopathy, and results from a prespecified analysis of the MAPLE-HCM study comparing aficamten versus metoprolol on exercise performance. Additionally, a poster presentation will discuss sociodemographic characteristics and healthcare costs in non-obstructive hypertrophic cardiomyopathy patients.

Cytokinetics (NASDAQ:CYTK) has priced an upsized $650.0 million convertible senior notes offering due 2031, increased from the initially announced $550.0 million. The notes will carry a 1.75% interest rate and an initial conversion price of $68.42 per share, representing a 37.5% premium over the last reported share price of $49.76.

The company will use approximately $402.5 million of the proceeds to refinance existing 3.50% 2027 notes, exchanging approximately $399.5 million of the 2027 notes and issuing 2,168,806 shares of common stock in private transactions. The remaining proceeds will support the potential commercial launch of aficamten and general corporate purposes.

The notes will mature on October 1, 2031, with interest payable semi-annually. Cytokinetics granted the initial purchasers an option to purchase an additional $100.0 million in notes within 13 days of the initial issuance.

Cytokinetics (NASDAQ: CYTK) has announced plans to offer $550.0 million in convertible senior notes due 2031 through a private placement to qualified institutional buyers. The company will also grant initial purchasers an option for an additional $82.5 million in notes.

The notes will be senior, unsecured obligations with semi-annual interest payments. Cytokinetics plans to use the proceeds to support the commercial launch of aficamten, expand its development program, advance its research pipeline, and for general corporate purposes. Additionally, the company intends to exchange a portion of its existing 3.50% convertible senior notes due 2027 through privately negotiated transactions.

Cytokinetics (NASDAQ:CYTK) presented new data for aficamten at ESC Congress 2025, strengthening its position as a potential treatment for obstructive hypertrophic cardiomyopathy (oHCM). Key findings from the MAPLE-HCM study showed aficamten's superiority over metoprolol in improving cardiac structure and function.

The data revealed that aficamten demonstrated a low annual incidence rate of atrial fibrillation at 1.5%, consistent with expected rates in HCM patients. Long-term safety data from FOREST-HCM showed sustained benefits across 352 patient-years of exposure, with significant improvements in cardiac function and patient symptoms. Notably, 93% of patients reported improvement in NYHA Functional Class at Week 96.

Aficamten is currently under FDA review with a PDUFA date of December 26, 2025.

Cytokinetics (NASDAQ:CYTK) announced positive Phase 3 results from MAPLE-HCM trial, comparing aficamten to metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study demonstrated aficamten's superiority over metoprolol across key metrics.

The trial's primary endpoint showed significant improvement in exercise capacity with aficamten (+1.1 mL/kg/min) compared to metoprolol (-1.2 mL/kg/min), with a difference of 2.3 mL/kg/min (p<0.0001). Notably, 51% of aficamten patients showed improved functional class versus 26% for metoprolol.

Aficamten demonstrated superiority in five of six secondary endpoints, including significant improvements in cardiac biomarkers and patient symptoms. The drug is currently under FDA review with a PDUFA date of December 26, 2025.